ArticlePharmaceuticals (Basel, Switzerland)2026
Discontinued BACE1 Inhibitors in Phase II/III Clinical Trials and AM-6494 (Preclinical) Towards Alzheimer's Disease Therapy: Repurposing Through Network Pharmacology and Molecular Docking Approach.
Samuel Chima Ugbaja et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.